Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy

• 3133 A pharmacogenetic interaction analysis of second-line chemotherapy with bevacizumab in metastatic colorectal cancer patients: Results from the randomized BEBYP trial Arianna Bandini, Paola Orlandi, Marco Scalese, Gianluca Masi, Federica Marmorino, Chiara Cremolini, Guido Bocci
• 3135 · PDF Comparative analysis of phenotypic markers of DPD activity as biomarkers of 5-FU toxicity Brianna Bembenek, Kelly Bouchonville, Carlo Largiadèr, Steven M. Offer
• 3136 · PDF Pharmacogenetic assays for personalized cancer treatment Abhishek Chadha, Jarvis Law, Zhiwei Wang, Max Mamroth, Zhenhua Shen, Khairuzzaman Bashar Mullah, Alexandre Vlassov, Anna Chikova
• 3137 Partial alternative splicing in carriers of DPYD rs75017182 explains modest association with severe 5-FU toxicity to 5-FU Lauryn Allyn Hahn, Ryan Schwartz, Hannah Marie Krause, Lulu Jiang, Brianna Bembenek, Kelly Bouchonville, Steven M. Offer
• 3138 · PDF CellMiner Cross-Database (CellMinerCDB) for Exploration of Patient-Derived Cancer Cell Line Pharmacogenomics Fathi Elloumi, William C. Reinhold, Sudhir Varma, Yanghsin Wang, Meric Kinali, Yashuhiro Arakawa, Yoshitaka Inoue, Mirit Aladjem, Yves Pommier, Augustin Luna
• 3139 · PDF drGT: Attention-guided gene assessment of drug response utilizing a drug-cell-gene heterogeneous network Yoshitaka Inoue, Hunmin Lee, Tianfan Fu, Rui Kuang, Augustin Luna
• 3140 · PDF Characterizing the critical role of enhancer-gene regulation in 5-fluorouracil toxicity and resistance Hannah Marie Krause, Julia Magee, Kelly Bouchonville, Lauryn Allyn Hahn, Ryan Jonathan Swartz, Brianna Bembenek, Lulu Jiang, Steven M. Offer
• 3141 · PDF Integrative genomic analysis reveals pharmacogenomic determinants of chemotherapy response Djuraev Farrukh, yashodhara Bhattacharya, Mohan Uttarwar, Sandhya Iyer, Hrishita Kothavade, Mina Darooei, Madhura Basavalingegowda, Hetakshi Kurani, Bharat Bhosale, Aarthi Ramesh, Gowhar Shafi
• 3142 Genomic determinants of response to the Wnt/Beta-catenin condensate modulator DPTX3186 in gastric cancer PDX models and implications for clinical development Francis Carpenter, Kip West, Doug Baumann, Adam Talbot, Thomas Durand-Reville, Karl Hsu, Ann Boija, Isaac Klein
• 3143 Co-targeting of two distinct androgen receptor-regulated signaling pathways as a therapeutic approach in prostate cancer Min-Yu Ko, Rachid Safi, Suzanne E. Wardell, Paige Watkinson, Isabel Jones, Brianna Richardson, John D. Norris, Donald P. McDonnell
• 3144 · PDF Targeting AR-SREBP crosstalk in prostate adenocarcinoma Sirisha Devarakonda, Prashanth Parupathi, Ekniel Francois, Avinash Kumar
• 3145 · PDF Pharmacologic inhibition of SREBP-driven lipogenesis suppresses metastatic progression in prostate cancer Prashanth Reddy Parupathi, Sirisha Devarakonda, Ekniel Francois, Avinash Kumar
• 3146 · PDF Targeting KMT2D enhances sensitivity to AKT inhibition in treatment resistant prostate cancer Abbas Jawadwala, Remi M. Adelaiye-Ogala, Surendra Gulla, Tej K. Sharma, Ephraim Jeremiah Gardner, Maddie Aust
• 3147 · PDF Pinostilbene exhibits anticancer activity in advanced prostate cancer Ekniel Francois, Prashanth Reddy Parupathi, Sirisha Devarakonda, Avinash Kumar
• 3148 Human blood micronucleated reticulocytes: Application as a pharmacodynamic biomarker for DNA double strand breaks in oncology drug development Jeffrey C. Bemis, Colette Baxter, Gillian Langford, Timothy A. Yap, Susanna Varkey Ulahannan, Nehal Lakhani, Babar Bashir, Kathleen N. Moore, Payal Shah, Svetlana Avlasevich, Dorothea Torous, Stephen Dertinger
• 3149 Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043 Colette L. Baxter, Timothy A. Yap, Susanna V. Ulahannan, Nehal Lakhani, Minal Barve, Erika P. Hamilton, Babar Bashir, Helen M. R. Robinson, Jayesh B. Majithiya, Paula Costales, Sarah V. Holt, Samantha C. Skelton, Marina Roy-Luzarraga, Jeff C. Bemis, Dorothea Torous, Svetlana Avlasevich, Susana Barriga, Bryony Harrop, Gillian A. Langford, Ian Smith, Graeme C. M. Smith
• 3150 InVEST44™ is a cost-effective in vitro safety panel that identifies off-target effects in early-stage drug discovery Julian R. Wooltorton, Afsara Ahona, Nicole Barbacane, Alex D'Andrea, Justin Lansberry, Cindy Lay, Paige Miller, John Ries, Jamin Steffen, Patricia Valentine
• 3151 High-throughput high-plex proteomic profiling of hepatocyte toxicity to oncologic drug compounds: A platform for toxicity assessment, immune risk prediction, and drug development acceleration Nicole Paul, Alyssa Rosenbloom, Nathaniel Robichaud, Kiran Edwardson, Nathan Chang, Narges Rashidi, Milad Dagher
• 3152 · PDF Development of iPSC-derived human liver organoids for preclinical drug testing and toxicology studies Fong Cheng Pan, Mahi Rahman, David Austin, Stephan Krieg, Luisa Marie A. Pfeifer, Anthony Saporita, Philip Hewitt, Steven Johnston, Laura Braeuninger-Weimer, Willem Kools, Vi Chu
• 3153 An integrated in vitro profiling platform for the simultaneous assessment of anti cancer efficacy and multi organ toxicity Xia Tu, Hao Wen, Dawei Yan, Jingna Ren, Qin Guo, Peichuan Zhang, Haiheng Dong
• 3154 · PDF Novel inhibitors of BCRP and P-gp found among drugs used in the treatment of cancer Martina Timonen, Feng Deng, Mikko Niemi
• 3155 Pharmacokinetic/pharmacodynamic correlation and biodistribution of Re (CO)3-phenformin compared with phenformin in murine PDAC model following equimolar intravenous dosing Amir Mohammad Gholizadeh, Fatima Dagher, Mikayla Skillman, Airong Li, Chun Li, Diana S-L Chow
• 3156 · PDF Pharmacokinetics of a series of anticancer agents in immunodeficient female NOD scid gamma mice Mohd Beshr Chama, Emily J. Koubek, Sarah A. Buhrow, Renee A. Schoon, Joel M. Reid
• 3157 Pharmacokinetic/pharmacodynamic correlation and biodistribution of paclitaxel and cyclopamine from M-CPA/PTX in HCC mice following multiple dosing Emanuel R. Baltrip, Lu Dai, Qiu-Xu Teng, Defeng Deng, Guodong Zhang, Chun Li, Diana S.-L. Chow
• 3158 Pharmacokinetic and biodistribution evaluation of nebivolol and dasatinib in the 4T1 triple-negative breast cancer model: Implications for drug-drug interaction Airong Li, Mikayla Skillman, Junhyoung Park, Fatima Dagher, Amir M. Gholizadeh, Emanuel Baltrip, Meghana Trivedi, Benny A. Kaipparettu, Diana S.-L. Chow
• 3160 · PDF Synergistic preclinical activity of dual CDK4/6 and mTORC1 inhibition in translocation renal cell carcinoma Shikha Gupta, Prateek Khanna, Eddy Saad, Renée Maria Saliby, Shatha AbuHammad, Jiao Li, Bingchen Li, Prathyusha Konda, Usman Ali Ahmed, Ananthan Sadagopan, Qingru Xu, Ziad El Bakouny, Wenxin Xu, Ramaprasad Srinivasan, Toni K. Choueiri, Srinivas R. Viswanathan
• 3162 · PDF Assessing statin sensitivity and hypoxia regulation in aggressive metastatic cancers Jimin Kim, Shannon Shams, Diana Vaca, Junhui Hu, Moe Ishihara, Khiara Threets, Robert Damoiseaux, Lily Wu

在完整检索应用中浏览本分会场 →